In accordance with our initial hypothesis, we reported that NLR was significantly higher in ASD children with a history of MIA than in ASD without MIA. Our results fostered preliminary evidence suggesting that ASD patients with a history of MIA have persistent peripheral inflammation and that NLR may be a potential biomarker of this immune dysregulation.
ASD by itself are associated with an immune dysregulation such as a decrease in Tregs and an increase in Th17 [20]. In animal models of ASD, MIA also induced long term increase of the Th17 [8] and decrease of Tregs in offspring [9]. This Tregs/Th17 imbalance results in a polarization of the immune balance toward a peripheral inflammation. Although we lack a control group of children without ASD born to mothers with MIA to independently assess MIA impact on the NLR of the offspring, recent basic neuroimmunology studies emphasized the importance of IL-17a in brain development but also in the homeostasis of cognitive function [21, 22]. Also, Tregs have been recently discovered in the perineuronal net and could play a fundamental role in neuronal homeostasis [23]. Moreover, in a mouse model of MIA-induced ASD, Tregs transplantation leads to normalization of autistic behaviors [24]. These data highlight that the immune dysregulation induced by MIA could have a pathophysiological impact in ASD children.
Using NLR, our study was the first to confirm preclinical findings in autistic individuals with a history of MIA. To our knowledge, only two previous studies have explored NLR in ASD. They reported no association with ASD but without considering the heterogeneity of individuals regarding MIA [15, 16]. The authors however showed a trend for a significant correlation between NLR and autistic symptom severity. Interestingly, MIA during pregnancy was also associated with severe ASD related features in the offspring [25]. Taken together with the literature, our results highlighted the potential role of immunity deregulation, and specifically the Tregs/Th17 imbalance, in the pathophysiology of ASD.
In our sample, we also observed more pregnancy complications in the MIA + group. Numerous examples in the literature emphasize that neurodevelopmental disorders may emerge through the addition of causal factors [5]. In animal studies, MIA is considered as a disease primer, making the offspring more susceptible to a second hit that might precipitate the rise of neurodevelopmental disorders [26]. The overrepresentation of perinatal hitches in the MIA + individuals may indirectly reflect this additive model of determinism in ASD [29]. Although no studies have investigated this hypothesis in the context of MIA, future cohort studies may try to further decipher the intrinsic link between MIA in pregnant mothers and the development of ASD in offspring. We advocate that they adopt a longitudinal perspective and take into account (i) 'secondary' events, (ii) clinical phenotyping of patients (severity of autism co-morbidity, ADHD co-morbidity) and (iii) include a deep immunophenotyping approach on larger samples. Our study has to be considered in light of its limitations. First, due to the intrinsic nature of our study, the collection of data and in particular events during pregnancy was retrospective and may therefore be subject to recall bias. Secondly, our sample size was small, particularly for the MIA + group. These two limitations were balanced by the use of stringent criteria on the definition of active MIA during pregnancy allowing (i) to temper recall bias and (ii) to define a homogeneous and powerful MIA + sample, enough to detect subtle differences between groups., in the general population infection during pregnancy is very frequent [28]. Thus, trying to make association between this common events with a less common occurrence (ASD in the offspring) carries the risk of false associations. It is important to note, however, that our results are consistent with those found in basic research studies. Fifth, the NLR cut-off used in categorical analysis is only validated in an adult population. To our knowledge, no such threshold exists for the pediatric population [29].